Trial · NCT07314385
NH002-mediated Sonoporation With Chemotherapy in Advanced Pancreatic Cancer
NCT07314385, Phase 1, Not yet recruiting, National Taiwan University Hospital
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. NH002-mediated Sonoporation With Chemotherapy in Advanced Pancreatic Cancer. Trials, record NCT07314385. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07314385
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- NH002-mediated Sonoporation With Chemotherapy in Advanced Pancreatic Cancer
- NCT number
- NCT07314385
- Status
- Not yet recruiting
- Phases
- Phase 1
- Enrollment
- 24 participants, estimated
- Lead sponsor
- National Taiwan University Hospital
- Conditions
- Pancreatic Adenocarcinoma Metastatic, Liver Metastasis
- Interventions
- nanoliposomal irinotecan+5-FU+leucovorin, NH002 (Perflutren Lipid Microspheres) Injectable Suspension, Aco Apache Ultrasound
- First posted
- 2026-01-02
- Last updated
- 2026-01-02
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | AE | within 28 days (Cycle 1) | Number of participants with treatment-related adverse events as assessed by CTCAE v5.0 |
| Primary | MTD | within 28 days (cycle 1) | To determine the maximum tolerated dose of NH002 in the 3+3 design according to assessment of dose-limiting toxicities with CTCAE v 5.0 |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers4
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07314385
GET https://conductscience.org/api/trials/v1/NCT07314385/registered